MDGL RSI Chart
Last 7 days
7.3%
Last 30 days
-3.5%
Last 90 days
-5.5%
Trailing 12 Months
-20.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2021 | 2.6M | 1.5M | 743.0K | 363.0K |
2020 | 9.9M | 8.1M | 6.1M | 4.3M |
2019 | 10.0M | 11.8M | 11.8M | 11.0M |
2018 | 1.2M | 2.3M | 4.9M | 7.7M |
2017 | 0 | 0 | 0 | 558.0K |
2016 | 0 | 0 | 0 | 0 |
2012 | 0 | 0 | 0 | 0 |
2011 | 12.4M | 9.9M | 8.2M | 7.6M |
2010 | 0 | 101.1M | 58.0M | 14.8M |
2009 | 0 | 0 | 0 | 144.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 08, 2024 | taub rebecca | acquired | 25,288 | 9.45 | 2,676 | pres., r&d, and cmo |
Apr 08, 2024 | friedman paul a | sold | -6,467,490 | 246 | -26,270 | - |
Apr 08, 2024 | friedman paul a | acquired | 248,252 | 9.45 | 26,270 | - |
Apr 08, 2024 | taub rebecca | sold | -658,258 | 245 | -2,676 | pres., r&d, and cmo |
Apr 05, 2024 | taub rebecca | acquired | 259,932 | 9.45 | 27,506 | pres., r&d, and cmo |
Apr 05, 2024 | friedman paul a | acquired | 260,943 | 9.45 | 27,613 | - |
Apr 05, 2024 | friedman paul a | sold | -6,721,080 | 243 | -27,613 | - |
Apr 05, 2024 | taub rebecca | sold | -6,693,790 | 243 | -27,506 | pres., r&d, and cmo |
Apr 04, 2024 | taub rebecca | acquired | 175,175 | 9.45 | 18,537 | pres., r&d, and cmo |
Apr 04, 2024 | taub rebecca | sold | -4,502,820 | 242 | -18,537 | pres., r&d, and cmo |
Which funds bought or sold MDGL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CASTLEARK MANAGEMENT LLC | new | - | 2,459,440 | 2,459,440 | 0.10% |
May 16, 2024 | COMERICA BANK | added | 615 | 87,110 | 99,220 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 0.36 | 443,058 | 3,241,600 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -88.4 | -43,451,000 | 6,716,320 | -% |
May 15, 2024 | Mariner, LLC | added | 108 | 411,114 | 703,116 | -% |
May 15, 2024 | BAKER BROS. ADVISORS LP | unchanged | - | 70,243,000 | 526,015,000 | 6.60% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | added | 7.86 | 4,820,220 | 24,511,300 | -% |
May 15, 2024 | PRELUDE CAPITAL MANAGEMENT, LLC | reduced | -32.13 | -150,447 | 543,693 | 0.03% |
May 15, 2024 | CAPITAL FUND MANAGEMENT S.A. | reduced | -40.85 | -1,554,560 | 3,344,680 | 0.01% |
May 15, 2024 | PERCEPTIVE ADVISORS LLC | added | 184 | 79,841,300 | 114,815,000 | 1.99% |
Unveiling Madrigal Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Madrigal Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.57 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Madrigal Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 |
Revenue | -13.3% | 52,000 | 60,000 | 91,000 | 160,000 | 432,000 | 823,000 | 1,204,000 | 1,870,000 | 2,214,000 | 2,766,000 | 3,005,000 | 3,039,000 | 2,979,000 | 2,821,000 | 1,166,000 | 705,000 | 216,000 | 174,000 | 92,000 | 76,000 | 59,000 |
Operating Expenses | 2.3% | 64,601,000 | 63,160,000 | 61,742,000 | 52,979,000 | 59,555,000 | 58,786,000 | 50,327,000 | 38,005,000 | 29,954,000 | 24,195,000 | 22,704,000 | 18,119,000 | 14,454,000 | 11,333,000 | 7,826,000 | - | - | - | - | - | - |
S&GA Expenses | 41.3% | 11,712,000 | 8,287,000 | 10,110,000 | 7,209,000 | 6,126,000 | 5,494,000 | 5,639,000 | 4,605,000 | 5,044,000 | 4,748,000 | 7,110,000 | 5,746,000 | 5,583,000 | 5,122,000 | 2,717,000 | 1,871,000 | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -2.3% | -64,549,000 | -63,100,000 | -61,651,000 | -52,546,000 | -59,123,000 | -57,963,000 | -49,023,000 | -36,135,000 | -27,740,000 | -21,429,000 | -19,699,000 | -15,080,000 | -11,475,000 | -8,512,000 | -6,460,000 | - | - | - | - | - | - |
Net Income Margin | -109.4% | -666 | -318 | -153 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -5.6% | -48,164,000 | -45,606,000 | -46,883,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 69.0% | 1,082 | 641 | 238 | 302 | 332 | 363 | 159 | 216 | 223 | 273 | 305 | 328 | 310 | 287 | 340 | 388 | 411 | 442 | 456 | 470 | 480 |
Current Assets | 68.5% | 1,074 | 637 | 235 | 302 | 331 | 361 | 157 | 215 | 221 | 272 | 303 | 326 | 308 | 285 | 338 | 387 | 409 | 440 | 455 | 469 | 478 |
Cash Equivalents | 523.0% | 623 | 100 | 62.00 | 77.00 | 113 | 332 | 59.00 | 53.00 | 42.00 | 36.00 | 49.00 | 34.00 | 44.00 | 54.00 | 109 | 62.00 | 67.00 | 47.00 | 89.00 | 73.00 | 47.00 |
Net PPE | 12.2% | 2.00 | 2.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -1.6% | 232 | 235 | 216 | 199 | 182 | 165 | 148 | 133 | 77.00 | 77.00 | 70.00 | 57.00 | 49.00 | 47.00 | 50.00 | 45.00 | 26.00 | 25.00 | 16.00 | 13.00 | 11.00 |
Current Liabilities | -3.5% | 114 | 119 | 100 | 100 | 98.00 | 116 | 99.00 | 84.00 | 77.00 | 77.00 | 69.00 | 57.00 | 49.00 | 47.00 | 49.00 | 45.00 | 26.00 | 25.00 | 15.00 | 12.00 | 10.00 |
Long Term Debt | 0.6% | 116 | 115 | 115 | 99.00 | 84.00 | 49.00 | 49.00 | 49.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 115 | 115 | 99.00 | 84.00 | 49.00 | 49.00 | 49.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | 109.9% | 851 | 405 | 22.00 | 104 | 150 | 197 | 11.00 | 84.00 | 146 | 196 | 235 | 271 | 261 | 240 | 290 | 343 | 385 | 417 | 440 | 457 | 469 |
Retained Earnings | -11.0% | -1,483 | -1,336 | -1,224 | -1,125 | -1,039 | -962 | -876 | -795 | -724 | -667 | -602 | -539 | -478 | -425 | -366 | -308 | -259 | -223 | -195 | -174 | -154 |
Additional Paid-In Capital | 34.1% | 2,335 | 1,741 | 1,246 | 1,229 | 1,190 | 1,160 | 888 | 880 | 871 | 863 | 838 | 810 | 739 | 665 | 656 | 650 | 644 | 640 | 636 | 631 | 623 |
Shares Outstanding | 0% | 20.00 | 20.00 | 18.00 | 18.00 | 18.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 3,158 | - | - | - | 985 | - | - | - | 819 | - | - | - | 1,130 | - | - | - | 884 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -86.6% | -149,157 | -79,933 | -84,920 | -75,310 | -84,067 | -58,515 | -59,069 | -57,360 | -49,913 | -48,051 | -45,556 | -46,881 | -43,429 | -54,947 | -47,850 | -24,258 | -30,506 | -12,282 | -11,324 | -11,540 | -6,478 |
Share Based Compensation | 34.0% | 19,902 | 14,852 | 12,660 | 10,973 | 11,250 | 8,082 | 8,122 | 7,944 | 7,477 | 6,356 | 6,242 | 8,179 | 6,096 | 5,134 | 5,061 | 5,689 | 4,846 | 4,032 | 4,950 | 7,755 | 6,022 |
Cashflow From Investing | 127.1% | 98,053 | -362,123 | 50,199 | -3,732 | -186,864 | 66,387 | 65,137 | 19,236 | 55,926 | 15,643 | 40,091 | -27,325 | -33,464 | -4,798 | 94,753 | 19,365 | 50,460 | -30,507 | 28,267 | 36,438 | -3,491 |
Cashflow From Financing | 19.5% | 573,706 | 479,916 | 19,580 | 42,930 | 52,690 | 264,337 | - | 49,114 | - | 19,503 | 21,099 | 63,541 | 67,094 | 4,629 | 350 | 109 | - | - | 35.00 | 117 | 83.00 |
Condensed Consolidated Statements Of Operations - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total revenues | $ 0 | $ 0 |
Operating expenses: | ||
Research and development | 71,237,000 | 62,154,000 |
Selling, general and administrative | 80,800,000 | 16,182,000 |
Total operating expenses | 152,037,000 | 78,336,000 |
Loss from operations | (152,037,000) | (78,336,000) |
Interest income | 8,334,000 | 3,776,000 |
Interest expense | (3,838,000) | (2,336,000) |
Net loss | $ (147,541,000) | $ (76,896,000) |
Net loss per common share: | ||
Basic net loss per common share (in dollars per share) | $ (7.38) | $ (4.23) |
Diluted net loss per common share (in dollars per share) | $ (7.38) | $ (4.23) |
Basic weighted average number of common shares outstanding (in shares) | 20,001,569 | 18,187,924 |
Diluted weighted average number of common shares outstanding (in shares) | 20,001,569 | 18,187,924 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 622,517 | $ 99,915 |
Marketable securities | 436,546 | 534,216 |
Inventory | 854 | 0 |
Prepaid expenses and other current assets | 14,035 | 3,150 |
Total current assets | 1,073,952 | 637,281 |
Property and equipment, net | 1,742 | 1,553 |
Intangible assets, net | 5,000 | 0 |
Right-of-use asset | 1,586 | 1,713 |
Total assets | 1,082,280 | 640,547 |
Current liabilities: | ||
Accounts payable | 21,528 | 28,041 |
Accrued expenses | 92,271 | 89,980 |
Lease liability | 542 | 527 |
Total current liabilities | 114,341 | 118,548 |
Long term liabilities: | ||
Loan payable, net of discount | 116,135 | 115,480 |
Lease liability | 1,045 | 1,186 |
Total long term liabilities | 117,180 | 116,666 |
Total liabilities | 231,521 | 235,214 |
Stockholders’ equity: | ||
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at September 30, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 0 | 0 |
Common stock, par value $0.0001 per share authorized: 200,000,000 at September 30, 2023 and December 31, 2022; 18,494,192 and 18,102,523 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 2 | 2 |
Additional paid-in-capital | 2,334,760 | 1,741,153 |
Accumulated other comprehensive income (loss) | (172) | 468 |
Accumulated deficit | (1,483,831) | (1,336,290) |
Total stockholders’ equity | 850,759 | 405,333 |
Total liabilities and stockholders’ equity | $ 1,082,280 | $ 640,547 |
 | madrigalpharma.com |
---|---|
 | Biotechnology |
 | 92 |